Project Grant R56HL171620
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$828K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to Boston Children's Hospital to conduct research on childhood interstitial lung disease (CHILD). The project aims to:
Define molecular profiles of CHILD using gene expression analysis of 300 lung biopsy samples to identify distinct patient subgroups. This will involve developing a CHILD classifier and assessing the clinical...
This $542,402 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify new drug compounds that can reverse gene expression patterns associated with idiopathic pulmonary fibrosis (IPF).
The grant aims to leverage transcriptomics data and artificial intelligence to discover drugs and novel compounds that may have anti-fibrotic effects in IPF. The proposed research includes in...
This $1,546,880 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulation of the myofibroblast gene program in idiopathic pulmonary fibrosis (IPF). The key objectives are to:
Determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF lungs, employing massively-parallel reporter assays to assess transcriptional activity of differentially-accessible...
This Project Grant award of $1,193,262.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel gene therapy treatment for idiopathic pulmonary fibrosis (IPF) using adeno-associated virus-mediated delivery of the SGPL1 gene.
The key products and services to be delivered under this award include:
Validating the efficacy of the SGPL1 gene therapy (AAV-SPL) in mouse models of IPF...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,872 Project Grant (under CFDA 93.837 - Cardiovascular Diseases Research) to Novomedix LLC to develop novel small molecule therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. The key objectives are to: 1) Confirm the efficacy of Novomedix's lead drug candidates in advanced cell-based assays, 2) Scale up production of the lead candidates, and 3) Demonstrate...
This $604,115 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund an observational study by The General Hospital Corporation (Massachusetts General Hospital) to determine if advanced PET and MRI imaging technologies can predict which individuals with non-IPF interstitial lung disease are at highest risk of developing progressive pulmonary fibrosis (PPF). The research aims to enable early...
This $5,715,866 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop novel, transformative therapies to reduce the burden of pulmonary fibrosis (PF). The grant supports a multi-institutional research program consisting of 4 projects and 3 cores to investigate the mechanisms driving the initiation and early progression of pre-clinical PF. The key products and services to be delivered include:
Utilizing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF). The primary objectives are to identify a clinical development candidate (CDC) compound that selectively and potently inhibits the myocardin-related transcription factor (MRTF) pathway, a critical pathway for the initiation and...
This $774,585 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to: 1) characterize the emergence and persistence of inflammatory fibroblasts in different models of lung injury and fibrosis, 2) determine the mechanisms driving the transition of inflammatory...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a 4-year $787,266 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Cedars-Sinai Medical Center. The grant is funding research to investigate the role of basal-like cells and the WNT7A signaling pathway in the development of idiopathic pulmonary fibrosis (IPF), a fatal lung disease. The research aims to test the hypothesis that dysregulated signaling in...